In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates

  • J Antibiot (Tokyo). 2019 Aug;72(8):600-604. doi: 10.1038/s41429-019-0188-6.
H Selcuk Ozger  1 ,  Tugba Cuhadar  2 ,  Serap Suzuk Yildiz  3  4 ,  Zehra Demirbas Gulmez  5 ,  Murat Dizbay  5 ,  Ozlem Guzel Tunccan  5 ,  Ayşe Kalkanci  2 ,  Husniye Simsek  3 ,  Ozlem Unaldi  4
Affiliations
  • 1. Department of Infectious Diseases and Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey. [email protected].
  • 2. Department of Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey.
  • 3. MoH General Directorate of Public Health, Department of National AMR Surveillance Laboratory, Ankara, Turkey.
  • 4. MoH General Directorate of Public Health, Central Laboratory, Ankara, Turkey.
  • 5. Department of Infectious Diseases and Clinical Microbiology, Gazi University School of Medicine, 06560, Ankara, Turkey.
PMID: 31028352 DOI: 10.1038/s41429-019-0188-6
Abstract

The synergistic activity of eravacycline in combination with colistin on carbapenem-resistant A. baumannii (CRAB) isolates was evaluated in this study. Minimum inhibitory concentrations (MICs) of eravacycline and colistin were determined by the broth microdilution method. MICs values ranged between 1 to 4 mg and 0.5 to 256 mg l-1 for eravacycline and colistin, respectively. In vitro synergy between eravacycline and colistin was evaluated by using the chequerboard methodology. Synergistic activity was found in 10% of the strains, and additive effect in 30%. No antagonism was detected. Similar activity was also observed in colistin-resistant CRAB isolates. The result of this study indicates that eravacycline and colistin combination may be a potential therapeutic option for the treatment of CRAB related infections.

Products